Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Emory Robinette

Sleep Medicine Abingdon, VA Medical Doctor

NPI 1942296645 CMS profile 133317

351 Court St, Abingdon, VA 24210

Open in the dashboard

General payments

$7,261

151 records reported · program years 2019–2025

Research payments

$1,484

Paid to them · 15 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,145,198 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Emory Robinette of Abingdon, VA is reported in the CMS Open Payments database as having received $7,261 across 151 general payments and $1,484 in research payments paid to them. Separately, studies naming them as principal investigator received $1,145,198 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 88th percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18 1
2024 General $21 1
2021 General $59 1
2020 General $479 28
2019 General $6,684 120
2019 Research $1,484 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Emory Robinette
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Emory Robinette were reported at $18. Among 670 Sleep Medicine profiles paid that year, the median was $439 and the middle half received between $127 and $1,274.

Show as a table
Year Emory Robinette Sleep Medicine median Middle half National median
2019 $6,684 $185 $66–$736 $163
2020 $479 $149 $46–$504 $114
2021 $59 $191 $62–$750 $132
2022 $0 $246 $92–$972 $149
2023 $0 $321 $119–$1,033 $160
2024 $21 $393 $111–$1,207 $164
2025 $18 $439 $127–$1,274 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca UK Limited $3,276 29 payments
  2. AstraZeneca Pharmaceuticals LP $2,295 23 payments
  3. GlaxoSmithKline, LLC. $406 25 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $315 17 payments
  5. Genentech USA, Inc. $266 16 payments
  6. Regeneron Healthcare Solutions, Inc. $156 7 payments
  7. Janssen Pharmaceuticals, Inc $107 7 payments
  8. Amgen Inc. $80 6 payments
  9. Actelion Pharmaceuticals US, Inc. $69 3 payments
  10. Genzyme Corporation $64 2 payments
  11. Other $229 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,636 137 payments
  2. Travel and Lodging $3,626 14 payments
Products named General payments · program years 2019–2025
  1. FASENRA $2,145 31 payments
  2. BEVESPI AEROSPHERE $1,644 4 payments
  3. TRELEGY ELLIPTA $253 11 payments
  4. SPIRIVA RESPIMAT $215 12 payments
  5. STIOLTO RESPIMAT $215 12 payments
  6. Xolair $209 15 payments
  7. DUPIXENT $156 7 payments
  8. Esbriet $155 12 payments
  9. XARELTO $107 7 payments
  10. INVOKANA $107 7 payments
  11. Other $1,015 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,484 15 payments

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$20,166

Medicare's payments for the services billed

Medicare patients

436

Average age 72

Services billed

963

249 women, 187 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 45%
Arthritis 45%
Ischemic heart disease 44%
Diabetes 39%
Chronic kidney disease 30%
Heart failure 26%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

166 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record